Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: anticancer gene therapy, MediGene.

S Hunt1

  • 1dshunt@easynet.co.uk

Current Opinion in Molecular Therapeutics
|November 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex opioid driven modulation of glutamatergic and cholinergic neurotransmission in a GABAergic brain nucleus associated with emotion, reward and addiction.

bioRxiv : the preprint server for biology·2025
Same author

Evolution of cortical neurons supporting human cognition.

Trends in cognitive sciences·2022
Same author

Verbal and General IQ Associate with Supragranular Layer Thickness and Cell Properties of the Left Temporal Cortex.

Cerebral cortex (New York, N.Y. : 1991)·2021
Same author

Fertility preservation in women with cancer and afterward.

Climacteric : the journal of the International Menopause Society·2019
Same author

Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis.

Oncogene·2018
Same author

Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin.

Journal of viral hepatitis·2017
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

MediGene is developing gene-modified cancer vaccines using recombinant adeno-associated virus (rAAV) vectors to stimulate the immune system. This approach aims to create a targeted antitumor response for treating melanoma and ovarian cancers.

Area of Science:

  • Oncology
  • Gene Therapy
  • Immunotherapy

Background:

  • Recombinant adeno-associated virus (rAAV) vectors are being explored for cancer treatment.
  • MediGene is developing rAAV-based therapies for melanoma and ovarian cancer.

Purpose of the Study:

  • To evaluate the potential of rAAV vectors in cancer therapy, specifically for melanoma and ovarian cancer.
  • To initiate a phase I/II trial for an rAAV-based malignant melanoma vaccine.

Main Methods:

  • Gene modification of autologous or allogeneic tumor cells using rAAV vectors to express immunomodulators.
  • In vitro expansion of gene-modified cells, followed by irradiation.
  • Reintroduction of modified cells into the host to elicit an antitumor immune response.

Related Experiment Videos

Main Results:

  • The therapy aims to boost the patient's immune response against their own tumor cells.
  • The approach is designed to generate a specific antitumor response.

Conclusions:

  • rAAV vectors show potential for developing novel cancer vaccines.
  • The strategy involves leveraging the patient's immune system to combat cancer through gene-modified cells.